SLC5A2 and type 2 diabetes mellitus: Compared whether the oral combination of an SGLT2 inhibitor (DAPA) and a DPP4 inhibitor (SAXA) could achieve similar glycemic control to basal insulin in T2DM patients poorly controlled with metformin, without causing an increase in hypoglycemia or body weight.